ABBV Stock: Unusual Options Activity Signals Bearish Hedge as AbbVie Trades Near Midpoint of 52-Week Range

By TrendSpider Editor

A single large put contract totaling $1,330,000 in premium has surfaced in AbbVie Inc. options trading today, drawing attention to potential downside positioning in the stock. ABBV is currently trading at $206.91, up a modest 0.33% on the session, sitting roughly in the middle of its 52-week range o

ABBV Stock: Unusual Options Activity Signals Bearish Hedge as AbbVie Trades Near Midpoint of 52-Week Range

A single large put contract totaling $1,330,000 in premium has surfaced in AbbVie Inc. options trading today, drawing attention to potential downside positioning in the stock. ABBV is currently trading at $206.91, up a modest 0.33% on the session, sitting roughly in the middle of its 52-week range of $164.39 to $244.81. The outsized open interest reading on this contract makes it the standout activity worth watching heading into the weekend.

Key Drivers of the ABBV Stock Move

• Main Catalyst: One unusual put contract was flagged today on ABBV with a $190 strike expiring October 16, 2026. The contract carries $1,330,000 in total premium, a size of 1,000 contracts, and an open interest reading of 1,389%, indicating the volume today dwarfs the existing open interest by a significant margin and signals a fresh, deliberate position rather than routine activity.
• Bull Case: The $190 strike sits roughly $16.91, or about 8.2%, below the current price of $206.91, meaning the stock has meaningful cushion before this put moves into the money. ABBV would also need to fall well below its current level to approach the 52-week low of $164.39, suggesting the broader trend has shown resilience.
• Bear Case: The sheer size of this position, $1,330,000 in premium on a single out-of-the-money put, suggests a well-capitalized trader is either hedging a large long position or making a directional bet on downside through October 2026. The October expiry gives the trade a long runway, implying the trader anticipates a potential catalyst or sustained pressure over the next several months rather than a near-term blip.

The forward setup for ABBV carries some notable complexity. The stock has already shed meaningful ground from its 52-week high of $244.81, sitting more than $37 below that peak, and has yet to reclaim decisive upside momentum. The October 2026 expiry on this put spans multiple potential catalysts, including upcoming earnings cycles and any pipeline or regulatory developments that could move the stock materially. AbbVie continues to navigate the post-Humira revenue transition, leaning on Skyrizi and Rinvoq as growth drivers, and any updates to that trajectory between now and fall could prove pivotal. Traders positioning this far out with this much premium suggest a conviction that current pricing may not fully reflect risks on the horizon.

ABBV Unusual Options Activity

• Contract: Put | Strike: $190 | Expiry: October 16, 2026 | Volume: 1,000 | Open Interest %: 1,389% above existing open interest | Premium: $1,330,000

This is the only unusual contract flagged today, with zero calls reported alongside it. The absence of any call-side activity reinforces the one-sided, bearish character of today's options flow in ABBV.

ABBV Seasonality

March has historically been a transitional period for large-cap pharmaceutical names as investors reposition ahead of mid-year pipeline readouts and conference season. A put positioned through October captures the full span of that activity, including what has historically been a volatile stretch for biotech and pharma equities in the summer months.

ABBV Relative Performance

ABBV's 0.33% gain today is modest and unlikely to stand out against broader market moves on a Friday session. With the stock at $206.91 against a 52-week high of $244.81, it has underperformed its own peak by roughly 15.5%, suggesting it has lagged the recovery seen in other large-cap names that have pushed closer to or through their annual highs. Until ABBV can reclaim levels meaningfully above current trading, the technical picture remains one of a stock working through a prolonged consolidation phase.